<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127890</url>
  </required_header>
  <id_info>
    <org_study_id>ELOWater</org_study_id>
    <nct_id>NCT04127890</nct_id>
  </id_info>
  <brief_title>ELO Water In Diabetes Care For Enhancement Of Blood Sugar Control</brief_title>
  <acronym>EDEN</acronym>
  <official_title>ELO Water In Diabetes Care For Enhancement Of Blood Sugar Control (EDEN Study) - A Double-Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ELO Water Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blinded, randomised and controlled trial evaluates the efficacy of
      oxygen-enriched ELO drinking water as an adjuvant modality in diabetes care for enhancement
      of glycemic control in patients with Type 2 diabetes mellitus. Adults with type 2 diabetes
      will be randomized to drink 1.5 L of either ELO water or normal drinking water for 24 weeks.
      The primary outcome is improvement in glycaemic control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Global diabetes mellitus prevalence is rapidly increasing. In 2015, IDF reported that
      Singapore has 12.8% of its population diagnosed with diabetes mellitus, of which more than 90
      percent are type 2 diabetes with underlying insulin resistance. With the aging population and
      increasing prevalence of obesity and sedentary lifestyles, the prevalence is expected to
      continue to rise.

      In vitro studies demonstrated that hypoxia creates a state of insulin resistance through HIF
      (Hypoxia Inducible Factor) transcription factor expression in adipocytes. Insulin sensitivity
      was shown to improve in type 2 diabetes patients and overweight non diabetic patients placed
      in a hyperbaric oxygen chamber.Increased water intake has been associated with lower HbA1c in
      the general population , and also with lower post-prandial glucose in type 2 diabetic
      individuals.

      This study aims to evaluate the effects of 1.5 L daily of ELO water, a drinking water
      enriched with molecular oxygen in a stable form, with a similar volume of bottled drinking
      water, on glycaemic control in adults with type 2 diabetes in Singapore.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Actual">May 28, 2018</completion_date>
  <primary_completion_date type="Actual">May 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of glycaemic control</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction in HbA1c and fasting plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction in weight</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 L of ELO Water to be drunk daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1.5 L of placebo bottled drinking water to be drunk daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ELO Water</intervention_name>
    <description>oxygen-enriched water</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo drinking water</intervention_name>
    <description>bottled drinking water</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 diabetes mellitus with HbA1c 8.0% to 11%, within the last 6 months

        Exclusion Criteria:

          1. Type 1 diabetes patients

          2. Pregnant or lactating women

          3. Comorbid conditions requiring fluid restriction to below 1.5 L daily

          4. Terminal illness with life expectancy less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Khoo, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changi General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 13, 2019</study_first_submitted>
  <study_first_submitted_qc>October 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxygen-enriched water</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

